J&J predicts Synthes deal will boost earnings; Cardium Therapeutics expands wound care gel market to Russia;

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

> Johnson & Johnson (J&J) expects it will complete its $20 billion-plus purchase of Swiss medical devicemaker Synthes on Thursday, and that the deal will slightly boost company profit this year instead of dragging on earnings. Story

> A Morgan Stanley analyst has increased the odds of the device tax repeal succeeding from 10% to 30%, even though many still believe the bill is a long shot this year. Story

> Israel's Mazor Robotics, via distributor BR Holdings, has gained Korean FDA clearance to market its Renaissance surgical guidance system for spine procedures. Release

> Tandem Diabetes Care in San Diego is rolling out its t:slim next-generation insulin pump for the commercial market, designed with a touch screen user interface. The FDA signed off on the product in November. Story

> Cochlear Americas won FDA approval for its new Nucleus CI422 electrode, which it bills as "the world's thinnest, full length electrode" for use with a cochlear implant. Release

Biotech News

 @FierceBiotech: The ethics of finding markers in a fetal genome. Commentary | Follow @FierceBiotech

 @JohnCFierce: Novartis is going to invest $700M in Malaysian biotechs? Really? Report | Follow @JohnCFierce

 @RyanMFierce: Sequoia-backed startup enters race to make sense of the genome. Article | Follow @RyanMFierce

> Upsher-Smith embraces biotech with $553M deal to buy Proximagen. News

> Rhythm banks $25M for mid-stage work on diabetes, obesity drugs. Story

> Merck preps FDA app after racking up positive PhIIIs on new sleep drug. Article

Pharma News

 @FiercePharma: Here's an offbeat pharma story: Sanofi's investor relations team won the prize in a Thomson Reuters financial contest--ReutersReport | Follow @FiercePharma

> Drugstores accuse Pfizer, Teva of blocking Effexor generics. Report

> Are the dog days over for Johnson & Johnson? More

> Big Pharma's Japanese sales gain as U.S., Europe lag. Story

Drug Delivery News

 @DamianFierce: One U.K. company is developing a chocolate-based drug delivery platform, and NIH has taken notice. Story | Follow @DamianFierce

> Zogenix signs co-promotion deal for needle-free migraine treatment. More

> Allergan looks to needle-free delivery for Botox. More

> J&J moves forward with next-gen insulin delivery. Item

Biomarkers News

> Cluster of genes is biomarker for breast cancer recurrence. Story

> Methylation marker tags leukemia outcomes. Article

> Gene signatures tag breast cancer drug response. News

> Scientists detect Down syndrome using mother's blood. More

And Finally... Cardium Therapeutics has inked a deal with Advanced Biosciences Research to market Cardium's Excellagen topical wound care gel in Russia and 9 additional countries that are part of the Commonwealth of Independent States. Release

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.